056 Mutli-dimensional prevention program after acute coronary syndrome (ELIPS)  by Keller, Pierre-Frédéric et al.
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2010) 2, 1-21 19
056
Mutli-dimensional prevention program after acute coronary syn-
drome (ELIPS)
Pierre-Frédéric Keller (1), Nicolas Rodondi (2), Reto Auer (2), Thomas
Perneger (3), Franck Schneider (4), Ariel Richard-Arlaud (4), Marco Roffi
(1), David Carballo (1), Sebastian Carballo (5), Christian Matter (6), Tho-
mas Luscher (6), Stephan Windecker (7), Pierre Vogt (8), Jacques Cornuz
(2), Gérard Waeber (9), Pierre Chopard (10), Jean-Claude Chevrolet (11),
François Mach (1)
(1) Hôpitaux Universitaires de Genève, Cardiologie, Genève, Suisse – (2)
Centre Hospitalier Universitaire Vaudois, Département de soins ambula-
toires et de médecine communautaire, Lausanne, Suisse – (3) Hôpitaux
Universitaires de Genève, Service d’épidémiologie, Genève 14, Suisse –
(4) Hôpitaux Universitaires de Genève, Service de Communication/Multi-
media, Genève, Suisse – (5) Hôpitaux Universitaires de Genève, Médecine
Interne Générale, Genève, Suisse – (6) Universitätsspital Zurich, Zurich,
Suisse – (7) Inselspital Bern, Berne, Suisse – (8) Centre Hospitalier Uni-
versitaire Vaudois, Cardiologie, Lausanne, Suisse – (9) Centre Hospita-
lier Universitaire Vaudois, Médecin Interne, Lausanne, Suisse – (10)
Hôpitaux Universitaires de Genève, direction de la qualité des soins,
Genève, Suisse – (11) Hôpitaux Universitaires de Genève, Soins Intensifs,
Genève, Suisse
Background: Guidelines recommend pharmacologic and lifestyle interven-
tions to reduce recurrence of events in patients with coronary and other athe-
rosclerotic vascular disease. Based on our systematic review of tested
interventions, we developed the ELIPS program, a multidimensional secon-
dary prevention program targeting multiple cardiovascular risk factors for
patients after an acute coronary syndrome (ACS). This programme targets an
increase in prescription rates by physicians and/or long term medication adhe-
rence by patients.
Objectives: To demonstrate the effectiveness of the ELIPS programme
(Multi-dimEnsionaL preventIon Program after Acute coronary Syndrome),
which aims at improving quality of care of patients admitted to hospital with
ACS in the Swiss setting.
Methods: A total of 2400 patients will be prospectively included in a mul-
ticenter study before and after the implementation of the ELIPS program with
a follow-up of 12 months. The primary outcome is a composite of death from
any cause, myocardial infarction, documented unstable angina requiring rehos-
pitalization, revascularization (performed at least 30 days after randomization),
and stroke. The secondary endpoints are the isolated endpoints of the primary
endpoint as well as cardiovascular mortality, and surrogate outcomes such as
cardiovascular risk factor control at follow-up.
Expected results: To demonstrate the benefits of the ELIPS program on
recurrence rate of cardiovascular events. These results will certainly lead to a
generalization of such programs in the field of atherosclerosis.
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Background: Renal artery stenosis (RAS) is a strong independent pre-
dictor of mortality in patients (pts) with coronary artery disease (CAD).
Aim of study: to develop and validate a score predicting RAS in patients
with CAD.
Methods: Three hundred consecutive pts (50 females) with significant
CAD underwent abdominal aortography following coronary angiography to
screen for significant RAS defined as luminal narrowing of > 50%. Univariate
and multivariate analyses were performed comparing pts with and without
RAS. Significant factors associated with RAS were included in constructing a
score that predicts RAS.
The score was internally validated in pts randomly selected from the entire
study group (validation group; n = 103), using ROC curves and the Hosmer-
Lemeshow goodness-of-fit test.
Results: Twenty-seven pts (9%) had a significant RAS. Univariate predic-
tors of significant RAS were: age > 65 years (OR = 4.5, p < 0.0001), hyper-
tension (OR = 3.6, p = 0.001), and female gender (OR = 3.6, p = 0.015). We
found a tendency of more prevalent renal insufficiency (37.1% vs. 21.5%; p =
0.05) and the presence of 2 or more significant CAD lesions (70.4% vs.
50.9%; p = 0.05) in pts with RAS.
Multivariate analysis showed that age > 65 years (OR = 4.1%, 95% CI =
1.6-10.3, p = 0.003) and hypertension (OR = 3.1, 95% CI = 1.2-7.7, p = 0.015)
were independent predictors of RAS. The ranged from 0 to 7: 2 points for age
> 65 years and hypertension 1 point for female gender, renal insufficiency, and
> 3-vessel disease). Internal validation showed a good performance (ROC
curve = 0.79 and Chi2 Lemeshow = 3.45). For a score < 2, the negative pre-
dictive value is 98%. Applying this criteria, 48.3% of our population would
not require systematic abdominal angiography.
Conclusion: The performance of our predictive score was good, and signi-
ficant reduction in the need to perform systematic abdominal aortography
could be expected with the use of this score.
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Objective: This study examined the effect of cyclosporine A used at the
time of reperfusion, on LV remodeling and function by cardiac magnetic reso-
nance (CMR) in the early days and several months after AMI.
Background: In a human study, administration of cyclosporine A at the
time of acute myocardial infarction (AMI) reperfusion was associated with a
smaller infarct size. However, experimental data suggest that cyclosporine A
has a detrimental effect on left ventricular remodeling.
Methods: 28 patients of the original cyclosporine A study had an acute
(day 5) and a follow-up (6 months) CMR study. Cine imaging was used to
determine LV volumes, mass, ejection fraction and myocardial wall thickness
in infarcted and remote non-infarcted myocardium, and late gadolinium ima-
ging was used to determine infarct size.
Results: There was a persistent reduction of the absolute infarct size at 6
months in the cyclosporine A group compared with the control group of
patients (29±15 grams VS 38±14 grams; P=0.04). There was a significant
reduction of LV end-systolic volume (and a trend for LV end-diastolic
volume; P=0.07) in the cyclosporine A group, compared with the control
group, both at day 5 and at 6 months after infarction. There was no significant
difference between the two groups in either global LV mass or regional wall
thickness of the remote non-infarcted myocardium at day 5 or at 6 months.
Attenuation of LV dilatation and improvement of LV ejection fraction by
cyclosporine A at 6 months were correlated with infarct size reduction.
Conclusion: Cyclosporine A used at the moment of AMI reperfusion per-
sistently reduces infarct size and does not have a detrimental effect on LV
remodeling
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